Lecozotan

Lecozotan

Systematic (IUPAC) name
4-Cyano-N-[(2R)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]propyl]-N-2-pyridinylbenzamide hydrochloride
Identifiers
CAS Number	434283-16-6
PubChem	CID: 10116877
ChemSpider	8292400
UNII	48854OTZ5E Y
KEGG	D04683 Y
Chemical data
Formula	C28H30ClN5O3
Molecular mass	520.021 g/mol
SMILES C[C@H](CN(C1=CC=CC=N1)C(=O)C2=CC=C(C=C2)C#N)N3CCN(CC3)C4=C5C(=CC=C4)OCCO5
InChI InChI=1S/C28H29N5O3/c1-21(31-13-15-32(16-14-31)24-5-4-6-25-27(24)36-18-17-35-25)20-33(26-7-2-3-12-30-26)28(34)23-10-8-22(19-29)9-11-23/h2-12,21H,13-18,20H2,1H3/t21-/m1/s1 Key:NRPQELCNMADTOZ-OAQYLSRUSA-N
(verify)

Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients. As of June 2008, the first Phase III clinical trial has been completed.

Method of action

Lecozotan is a competitive, selective 5-HT_1A receptor antagonist which enhances the potassium-stimulated release of acetylcholine and glutamate.